Enterprise Value

4.062B

Cash

266.5M

Avg Qtr Burn

-91.69M

Short % of Float

37.70%

Insider Ownership

79.62%

Institutional Own.

8.85%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Anktiva (N-803) Details
Bladder cancer, Cancer

Big Mover™

Susp. Mover™

PDUFA

Approval decision

PD-L1 t-haNK Details
Pancreatic cancer, Cancer

Phase 2/3

Update

hAd5-COVID-19 Details
Vaccine, COVID-19

Failed

Discontinued

N-803 (Anktiva), haNK and Avelumab Details
Metastatic merkel cell carcinoma, Insomnia, Mood disorders, Liver transplant, Cancer

Failed

Discontinued

Anktiva (N-803) + KEYTRUDA Details
Non-small cell lung carcinoma, Cancer, Solid tumor/s

Failed

Discontinued